comparemela.com

Latest Breaking News On - Prelude corporation - Page 3 : comparemela.com

PreludeDx™ to Present Multiple Presentations at the 2023

PreludeDx today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS)..

Australia
Texas
United-states
San-antonio
Cory-dunn
Yvonne-zissiadis
Troy-bremer
Dan-forche
Andrew-wade
Henryb-gonzalez-convention-center
University-of-california-san-francisco
National-cancer-institute

PreludeDx™ to Present New DCISionRT® Comparative Data in

Data to Address Limitations in the Applications of Clinicopathologic Factors .

Laguna-hills
California
United-states
Michigan
University-of-california-san-francisco
San-diego
San-diego-convention-center
Franka-vicini
Dan-forche
Cory-dunn
Chirags-shah
Troy-bremer

Strong Analytical Validation Data Further Supports Use of DCISionRT® to Guide Shared Decision-Making for DCIS Therapeutic Management

/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that.

United-states
Dan-forche
Cory-dunn
Chirag-shah
Andrew-wade
Prnewswire-prelude-corporation-preludedx
Prelude-corporation
Instagram
Linkedin
Department-of-radiation-oncology
University-of-california-san-francisco
National-institutes-of-health

PreludeDx Presents Comparative Data Analyzing Racial/Ethnic Radiation Therapy Treatment Recommendation Changes using DCISionRT

Results show Black women had significantly higher rates of radiation therapy recommendation compared to White women with similar biosignature scores

Boston
Massachusetts
United-states
Dan-forche
Pat-whitworth
Johnb-hynes-veterans-memorial-convention-center
Prelude-corporation-preludedx
University-of-tennessee
University-of-california-san-francisco
Nashville-breast-center
National-cancer-institute
Prelude-corporation

DCISionRT® by PreludeDx™ Receives Advanced Diagnostic Laboratory Test (ADLT) Status Approval from the Centers for Medicare & Medicaid Services

/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that.

United-states
Dan-forche
Cory-dunn
Andrew-wade
National-cancer-institute
Linkedin
Prnewswire-prelude-corporation-preludedx
Prelude-corporation
Centers-for-medicare-medicaid-services
University-of-california-san-francisco
Laboratory-test
Facebook

vimarsana © 2020. All Rights Reserved.